SEC Form 4 · accession 0001209191-18-051471
Verrica Pharmaceuticals Inc. · VRCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Linda Palczuk
Officer — Chief Operating Officer
Period of report
Sep 17, 2018
Accepted (ET)
Sep 18, 2018 · 4:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660334
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 17, 2018 | P | 2,500 | $16.52 | A | 5,500 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $16.52 to $16.55, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F2Consists of 3,000 shares of common stock held by Ms. Palczuk and 2,500 shares of common stock held by Ms. Palczuk jointly with her spouse.